By Fineline Cube 
Lepu Medical Technology (SHE: 300003), a leading Chinese provider of cardiovascular disease solutions, announced it has signed a comprehensive licensing agreement with domestic biopharmaceutical company Bio-Thera Solutions Inc. (SHA: 688177) to acquire all rights, assets, and business related to Betagrin (batifiban), a recently approved antiplatelet therapy for acute coronary syndrome.
Transaction Details
| Item | Detail |
|---|---|
| Acquirer | Lepu Medical Technology (SHE: 300003) |
| Licensor | Bio-Thera Solutions Inc. (SHA: 688177) |
| Upfront Payment | RMB 450 million (USD 66 million) |
| Milestone Structure | Single-digit percentage of annual net sales |
| Revenue Sharing Period | Up to 10 years from commercial launch |
| Asset Acquired | Betagrin (batifiban) – all rights, assets, and business |
Product Profile & Regulatory Status
Betagrin (batifiban) is a peptide-based β3 integrin receptor inhibitor that received NMPA approval in June 2024 for a specific high-risk cardiovascular indication:
- Indication: Patients with acute coronary syndrome undergoing percutaneous coronary intervention (PCI), including coronary artery stent placement
- Clinical Benefit: Reduces risk of critical PCI complications including:
- Acute occlusion
- In-stent thrombosis
- No-reflow phenomenon
- Slow-flow phenomenon
- Mechanism: Selective inhibition of β3 integrin receptors on platelets, preventing platelet aggregation during high-risk vascular procedures
Strategic Rationale
- Portfolio Synergy: Acquisition aligns perfectly with Lepu’s core focus on cardiovascular disease solutions and interventional cardiology
- Commercial Integration: Lepu’s established hospital distribution network and relationships with interventional cardiologists provide immediate commercial leverage
- Market Opportunity: Addresses unmet needs in PCI procedures where current antiplatelet therapies may be insufficient to prevent acute complications
- Vertical Integration: Combines Lepu’s medical device expertise with pharmaceutical solutions for comprehensive cardiovascular care
Market Analysis
The acute coronary syndrome market in China represents significant growth potential due to rising cardiovascular disease prevalence and increasing adoption of advanced interventional procedures. Key competitive advantages include:
- Recent Approval: June 2024 NMPA approval positions Betagrin as a modern therapeutic option
- Specific Indication: Targeted use in high-risk PCI procedures creates a focused commercial strategy
- Safety Profile: Peptide-based mechanism may offer improved safety compared to traditional antiplatelet agents
- Hospital Focus: Natural fit within Lepu’s existing hospital-centric commercial model
Financial Implications
The deal structure provides attractive economics for both parties:
- Bio-Thera: Receives substantial upfront payment while retaining long-term revenue participation
- Lepu: Gains immediate access to an approved cardiovascular drug with established clinical utility and regulatory pathway
- Revenue Potential: Single-digit royalty on net sales over 10 years creates sustainable long-term value creation
Industry Outlook
This transaction reflects the growing trend of strategic asset optimization among Chinese pharmaceutical companies, where specialized firms focus on their core competencies while divesting non-core assets to better-positioned partners.
For Lepu, the acquisition represents a strategic expansion from medical devices into pharmaceutical solutions, creating opportunities for integrated cardiovascular care offerings that combine diagnostic, interventional, and therapeutic components.
Forward-Looking Statements
This brief contains forward-looking statements regarding commercial performance, revenue projections, and market opportunities for Betagrin. Actual results may differ due to risks including market adoption rates, competitive pressures, pricing dynamics, and regulatory compliance requirements in China’s cardiovascular therapeutics market.-Fineline Info & Tech